Literature DB >> 8930358

Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology.

R A Shiurba1, K Ishiguro, M Takahashi, K Sato, E T Spooner, M Mercken, R Yoshida, T R Wheelock, H Yanagawa, K Imahori, R A Nixon.   

Abstract

One unique phosphorylation site consistently found in paired helical filament tau, serine 413, is modified by tau protein kinase I/glycogen synthase kinase-3 beta but no other known tau kinase. Here we present immunocytochemistry from Alzheimer's disease brains showing that focal subpopulations of hippocampal CA1 pyramidal neurons and neuritic plaques are strongly reactive for tau protein kinase I/glycogen synthase kinase-3 beta and tau phosphoserine 413 in early stages of pathology. Colocalization of these epitopes suggests that tau protein kinase I/glycogen synthase kinase-3 beta abnormally phosphorylates tau and is in a position to disrupt neuronal metabolism in anatomical areas vulnerable to Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930358     DOI: 10.1016/0006-8993(96)00717-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.

Authors:  Annamaria Lanzillotta; Ilenia Sarnico; Marina Benarese; Caterina Branca; Cristina Baiguera; Birgit Hutter-Paier; Manfred Windisch; Pierfranco Spano; Bruno Pietro Imbimbo; Marina Pizzi
Journal:  J Mol Neurosci       Date:  2010-12-22       Impact factor: 3.444

Review 2.  Changes in the ageing brain in health and disease.

Authors:  B H Anderton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-12-29       Impact factor: 6.237

3.  Frontiers in Alzheimer's disease therapeutics.

Authors:  Jeremy G Stone; Gemma Casadesus; Kasia Gustaw-Rothenberg; Sandra L Siedlak; Xinglong Wang; Xiongwei Zhu; George Perry; Rudy J Castellani; Mark A Smith
Journal:  Ther Adv Chronic Dis       Date:  2011-01-01       Impact factor: 5.091

4.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.

Authors:  J J Lucas; F Hernández; P Gómez-Ramos; M A Morán; R Hen; J Avila
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

5.  Light and electron microscopy study of glycogen synthase kinase-3beta in the mouse brain.

Authors:  Emma Perez-Costas; Johanna C Gandy; Miguel Melendez-Ferro; Rosalinda C Roberts; Gautam N Bijur
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

6.  Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau.

Authors:  A Takashima; M Murayama; O Murayama; T Kohno; T Honda; K Yasutake; N Nihonmatsu; M Mercken; H Yamaguchi; S Sugihara; B Wolozin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

Authors:  Shuxin Hu; Aynun N Begum; Mychica R Jones; Mike S Oh; Walter K Beech; Beverly Hudspeth Beech; Fusheng Yang; Pingping Chen; Oliver J Ubeda; Peter C Kim; Peter Davies; Qiulan Ma; Greg M Cole; Sally A Frautschy
Journal:  Neurobiol Dis       Date:  2008-11-05       Impact factor: 5.996

Review 8.  Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis.

Authors:  Scott A Small; Karen Duff
Journal:  Neuron       Date:  2008-11-26       Impact factor: 17.173

9.  The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain.

Authors:  Dylan Warren Maixner; Han-Rong Weng
Journal:  J Pharm Pharmacol (Los Angel)       Date:  2013

10.  Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression.

Authors:  Mala V Rao; Panaiyur S Mohan; Corrinne M Peterhoff; Dun-Sheng Yang; Stephen D Schmidt; Philip H Stavrides; Jabbar Campbell; Yuanxin Chen; Ying Jiang; Peter A Paskevich; Anne M Cataldo; Vahram Haroutunian; Ralph A Nixon
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.